Who is sponsoring NCT03081676?

NCT03081676 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT03081676?

Interventions in NCT03081676: Glimepiride 1Mg Tablet, Glucagon-like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Placebo Oral Tablet, Placebo infusion.

What condition does NCT03081676 study?

NCT03081676 studies Maturity-Onset Diabetes of the Young, Type 3.

Is NCT03081676 still recruiting?

NCT03081676 is currently completed. Last updated 27 June 2019.

Last reviewed 2019-06-27 · How we verify

NCT03081676: HNF1A-Clamp

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Completed NA Last updated 27 June 2019

What this trial tests

NA trial testing Glimepiride 1Mg Tablet in Maturity-Onset Diabetes of the Young, Type 3 in 20 participants. Completed in 1 June 2018.

Timeline

8 March 2017

Primary endpoint
1 June 2018

1 June 2018

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	20
Start date	8 March 2017
Primary completion	1 June 2018
Estimated completion	1 June 2018
Sites	1 location across Denmark

Drugs / interventions tested

Glimepiride 1Mg Tablet — full drug profile →
Glucagon-like Peptide-1
Glucose-Dependent Insulinotropic Polypeptide — full drug profile →
Placebo Oral Tablet — full drug profile →
Placebo infusion — full drug profile →

Conditions studied

Maturity-Onset Diabetes of the Young, Type 3 — all drugs for Maturity-Onset Diabetes of the Young, Type 3 →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

18 and older, any sex, with Maturity-Onset Diabetes of the Young, Type 3. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes. The aim of this study is to evaluate the effects of supra-physiological levels of GIP and GLP-1, respectively, on insulin and glucagon secretion at fasting plasma glucose (FPG) and "post-prandial" PG levels (1.5 × FPG) in patients with HNF1A-diabetes and matched healthy controls treated with or without a low dose of glimepiride (sulphonylurea). In addition, we will evaluate the maximal insulin and glucagon secretory capacity in both groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers.
Christensen AS, Hædersdal S, Storgaard H, Rose K, et al · · 2020 · cited 18× · PMID 32518064 · DOI 10.2337/db20-0074

Verify or expand the search:

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03081676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 27 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03081676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing